1998
DOI: 10.1016/s0009-9236(98)90155-2
|View full text |Cite
|
Sign up to set email alerts
|

Cognitive performance in elderly subjects after a single dose of befloxatone, a new reversible selective monoamine oxidase A inhibitor*

Abstract: Contrary to tricyclic antidepressants, whose deleterious effects are greater in elderly subjects, this study demonstrated the safety of befloxatone on cognition and psychomotor performance in elderly subjects.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0

Year Published

2002
2002
2018
2018

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 15 publications
(7 citation statements)
references
References 39 publications
0
7
0
Order By: Relevance
“…Concern about hypertensive crises led to the development of reversible inhibitors of MAO-A (RIMAs). Because tyramine still has competitive access to the active site on MAO-A and the 'cheese effect' is thus avoided, RIMAs such as moclobemide are better tolerated by at-risk populations, particularly the elderly, including those with cognitive deficits [142,143]. RIMAs have a further advantage over irreversible inhibitors in that there is usually full recovery of brain MAO within 24 hours after cessation of treatment [144], which is an important consideration if transferring a patient onto a drug regimen that may be contraindicated with elevated levels of biogenic amines.…”
Section: First-generation (Irreversible) Versus Newer Reversible Inhimentioning
confidence: 99%
See 1 more Smart Citation
“…Concern about hypertensive crises led to the development of reversible inhibitors of MAO-A (RIMAs). Because tyramine still has competitive access to the active site on MAO-A and the 'cheese effect' is thus avoided, RIMAs such as moclobemide are better tolerated by at-risk populations, particularly the elderly, including those with cognitive deficits [142,143]. RIMAs have a further advantage over irreversible inhibitors in that there is usually full recovery of brain MAO within 24 hours after cessation of treatment [144], which is an important consideration if transferring a patient onto a drug regimen that may be contraindicated with elevated levels of biogenic amines.…”
Section: First-generation (Irreversible) Versus Newer Reversible Inhimentioning
confidence: 99%
“…This suggests that MAO inhibitors could be useful adjunctive drug therapies in AD. RIMAs are particularly efficacious in treating depression [142] and cognitive disorders [143] in the elderly, and are potential anti-apoptotic agents [150]. The selective MAO-A inhibitor clorgyline inhibits glutamate-induced excitotoxicity [151] as well as apoptosis induced by serum starvation [110,150] and by the ADrelated -amyloid peptide in vitro [15], and protects against damage caused by the mitochondrial toxin malonate in vivo [152].…”
Section: First-generation (Irreversible) Versus Newer Reversible Inhimentioning
confidence: 99%
“…This latter association has been re-confirmed recently using two-photon imaging in the 5xFAD mouse model of AD ( Kim et al, 2016 ). Reversible inhibitors of MAO-A, such as moclobemide, have shown modest results in elderly individuals, including those presenting with cognitive deficits ( Rosenzweig et al, 1998 ; Gareri et al, 2000 ), whereas inhibitors of MAO-B, such as l-deprenyl, might provide benefit in the early stages of clinical neurodegenerative diseases, such as Parkinson’s disease ( Magyar et al, 2004 ; Youdim et al, 2006 ) and mild AD-type dementia ( Riederer et al, 2004 ).…”
Section: Introductionmentioning
confidence: 99%
“…Not surprisingly, MAO-A, which is often targeted for the treatment of depression, is also a potential risk factor for late-onset AD [ 15 - 18 ]. In contrast to irreversible inhibitors of MAO-A such as clorgyline, reversible inhibitors such as moclobemide are better tolerated and have been particularly efficacious in treating depression [ 19 , 20 ] and cognitive disorders [ 21 ] in the elderly. In addition, they protect against apoptosis [ 22 ] and glutamate-induced excitotoxicity [ 23 ] in vitro .…”
Section: Introductionmentioning
confidence: 99%